From: Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
Clinical trial ID | Phase | Setting | Regimen | Endpoint |
---|---|---|---|---|
NCT03382561 | II | ED-SCLC | CE vs CE plus nivolumab | PFS |
NCT02580994 (REACTION) | II | ED-SCLC | CE vs CE plus pembrolizumab | PFS |
NCT02934503 | II | ED-SCLC | CE plus pembrolizumab +/− RT | PD-L1 changes |
NCT03066778 (KEYNOTE-604) | III | ED-SCLC | CE plus pembrolizumab/placebo | PFS OS |
NCT02763579 | III | ED-SCLC | CE plus atezolizumab/placebo | PFS OS |
NCT03043872 | III | ED-SCLC | CE vs CE plus durvalumab +/−tremelimumab | PFS OS |
NCT02402920 | I | LD-SCLC | CE-RT plus pembrolizumab | MTD |